DiFUSION Technologies Announces Breakthrough Medical Polymer |
DiFUSION Technologies, Inc
111 Cooperative Way, Suite 250
Georgetown, TX, 78626
USA
Press release date: September 18, 2012
CleanFUZE(TM) Implantable Antimicrobial Biomaterial
GEORGETOWN, Texas - DiFusion announced today the completion of a series of in vivo and in vitro clinical tests which substantiate their claim that CleanFUZE resists surgical infection and promotes bone growth. "Our clinical tests have shown repeatedly that we have a new biomaterial which eradicates MRSA bacterium 99.998%," says Joseph Crudden, PhD, Vice President of Research at DiFusion. CleanFUZE is a new load-bearing polymer from which any orthopedic or dental implant can be engineered.
Hospital administrations, insurers and the public are becoming increasingly aware that surgical site infections (SSIs) pose an enormous issue as the 4th largest cause of death in the US with a higher mortality rate than auto accidents, breast cancer and AIDS - combined. Additionally, new Medicare reimbursement penalties for hospitals with high infection rates go into effect next month. CleanFUZE(TM) is the first material-based solution to actively kill MRSA while preventing biofilm adhesion.
According to Professor Hans Jorg Meisel, M.D., PhD, theDirector for the Center of Neurosciences and the Chair of the Department of Neurosurgery at BG-Clinic Bergmannstrost, Halle, Germany, "An orthobiologic material that resists infection and osteointegrates with bone would be the holy-grail of orthopedics. What more could we ask of an implant or material?"
DiFusion's CEO, Derrick Johns, claims that "CleanFUZE will first be introduced in the European Union via CE Mark in 2013 with subsequent FDA clearance in 2014."
About DiFusion Technologies, Inc.
Founded in 2008 in Austin, Texas, DiFusion Technologies, Inc. is a medical device company focused on reducing the rising incidence of surgical site infections in orthopedic and spine surgery through the development of a suite of patented antimicrobial orthobiologic polymeric implants. Initially focusing on the multi-billion dollar spinal implant market, the company has developed a technology with applicability across a variety of orthopedic segments using well characterized implants with benefits for the patient, surgeon, hospital and payer. For more information about DiFusion Technologies, visit www.difusiontech.com. CleanFUZE is not FDA approved for sale in the US.
DiFusion Media & Company Contact:
Karyl Fowler
Executive Assistant/Office Manager
Office: 512-863-7777
customerservice@difusiontech.com
SOURCE
DiFUSION Technologies, Inc.
Web Site: http://www.difusiontech.com
|
|
|
|
|
|
